Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Vanda Pharmaceuticals Inc.    VNDA

VANDA PHARMACEUTICALS INC.

(VNDA)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

Wolf Popper LLP : Announces Investigation on Behalf of Investors in Vanda Pharmaceuticals Inc.

share with twitter share with LinkedIn share with facebook
share via e-mail
0
02/12/2019 | 08:33am EDT

NEW YORK, Feb. 12, 2019 /PRNewswire/ -- Wolf Popper LLP is investigating potential securities fraud claims on behalf of purchasers of Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) securities from December 22, 2014 through February 8, 2019, who have incurred losses on their investments.

In March 2017, a qui tam whistleblower complaint was filed under seal against Vanda Pharmaceuticals, Inc. ("Vanda"). The qui tam action was unsealed on January 28, 2019. Shortly after trading began on February 11, 2019, Aurelius Value published a report entitled "Vanda: In the Land of The Blind, The One-Eyed Man is King." The report summarized the whistleblower complaint and said "Vanda has engaged in a series of fraudulent schemes, some personally orchestrated by Polymeropoulos himself, to defraud government payors. The allegations describe illegal off-label promotion of both of Vanda's drugs, Vanda's participation in a fraud involving doctors writing hundreds of "fake prescriptions" and pocketing cash using Vanda issued copay cards, falsified documents in internal systems, and resignations of senior executives who refused to participate in illegal activity."

As a result of this news, Vanda's stock price fell on Monday February 11, 2019, by $0.95 per share or 5% on heavy volume.

Vanda investors should contact Robert Finkel at (212) 759-4600 or (877) 370-7703 or at rfinkel@wolfpopper.com.

Wolf Popper has successfully recovered billions of dollars for defrauded investors.  The firm's reputation and expertise have been repeatedly recognized by the courts, which have appointed the firm to major positions in securities litigation.  See www.wolfpopper.com.

Attorney Advertising: Prior Results Do Not Guarantee A Similar Outcome.

Wolf Popper LLP
Robert C. Finkel
845 Third Avenue
New York, NY 10022
Tel.: (212) 451-9620
Tel.: (877) 370-7703
Fax: (877) 370-7704
Email: rfinkel@wolfpopper.com

 

Cision
View original content:http://www.prnewswire.com/news-releases/wolf-popper-llp-announces-investigation-on-behalf-of-investors-in-vanda-pharmaceuticals-inc-300794056.html

SOURCE Wolf Popper LLP


© PRNewswire 2019
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on VANDA PHARMACEUTICALS INC.
04/19VANDA PHARMACEUTICALS : Glancy Prongay & Murray Reminds Investors of Looming Dea..
BU
04/18VANDA PHARMACEUTICALS : to Announce First Quarter 2019 Financial Results on May ..
PR
04/09LEAD PLAINTIFF DEADLINE ALERT : Faruqi & Faruqi, LLP Encourages Investors Who Su..
BU
04/06Kirby McInerney LLP Reminds Investors That a Class Action Lawsuit Has Been Fi..
BU
04/03VANDA PHARMACEUTICALS : Hagens Berman Reminds Vanda Pharmaceuticals (VNDA) Inves..
PR
03/29DEADLINE REMINDER : The Law Offices of Howard G. Smith Reminds Investors of Loom..
BU
03/07GLANCY PRONGAY & MURRAY LLP : Announces the Filing of a Securities Class Action ..
BU
03/07VNDA LAWSUIT ALERT : Rosen Law Firm Files Securities Class Action Lawsuit Agains..
PR
03/07VANDA PHARMACEUTICALS : to Present at the Cowen and Company 39th Annual Health C..
PR
03/07(VNDA) ALERT : Johnson Fistel Reminds Investors of Deadline in the Class Action ..
PR
More news